Exelixis (EXEL) delivered earnings and revenue surprises of -36.84% and -10.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Exelixis: Q3 Earnings Insights

04:50pm, Tuesday, 02'nd Nov 2021

Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Is a Surprise Coming for Exelixis (EXEL) This Earnings Season?

12:15pm, Monday, 01'st Nov 2021

Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 Biotech Stocks That Could Make You Richer

06:00am, Saturday, 30'th Oct 2021

The best may be yet to come for these companies.

5 Mid-Cap Growth Stocks Set to Outperform

06:13pm, Tuesday, 19'th Oct 2021

Over the past year, the U.S. stock market has charged higher and higher as the economy has recovered from the onset of the Covid-19 pandemic, as shown by the S&P 500's 30% gain over this period.

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's Lymphoma

08:00am, Thursday, 14'th Oct 2021

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today announced that Exelixis has exercised its exclusive option under the compan

4 Growth Stocks With 187% to 434% Upside, According to Wall Street

05:51am, Wednesday, 13'th Oct 2021

Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.

Exelixis: Regaining Top Spot In Renal Cell Carcinoma

12:39am, Saturday, 25'th Sep 2021

Exelixis' climb to stardom began with a strong Cabometyx first-line presence in renal cell carcinoma, but soon dwindled due to the arrival of immunotherapy. Exelixis was pushed back to second line.

Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation

03:13pm, Monday, 20'th Sep 2021

The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers patients with locally advanced or metastatic

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021

11:30am, Monday, 20'th Sep 2021

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX® (cabozantinib) in patients with previously treate

Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021

07:30am, Saturday, 18'th Sep 2021

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) in combinatio

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by